Login / Signup

Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea.

Michael CamilleriSara Linker NordDuane BurtonIbironke OduyeboYiming ZhangJin ChenKoeun ImPrafulla BhadMichael K BadmanDavid S SandersJulian R F Walters
Published in: Alimentary pharmacology & therapeutics (2020)
Tropifexor 60 µg once daily had acceptable safety and tolerability. Changes in FGF19 and C4 showed effective target engagement; however, higher doses may be required to observe stool frequency changes. Slowing of ascending colon emptying suggests therapeutic potential of tropifexor in patients with primary bile acid diarrhoea. ClinicalTrials.gov number: NCT02713243.
Keyphrases